검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cyclin-Dependent Kinase 4 Inhibitor (Cyclin-Dependent Kinase 4 Inhibitor) SWOG Cancer Research Network·HER2 ORR 57.98% |
|---|---|
Overview Program | Cyclin-Dependent Kinase 4 Inhibitor |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | TArgeting Chimera (PROTAC) estrogen receptor |
MoA Biomarker | biomarker, Cyclin-dependent kinase 4 inhibitor A (p16INK4a) |
PK/PD Species | Mouse, ration assay, and a subcutaneous xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse, ration assay, and a subcutaneous xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Vepdegestrant for the treatment of HR+/HER2- breast cancer.. The treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer has been improved through the development of endocrine therapy (ET) and targeted agents. However, resistance to ET, particularly caused by ESR1 mutations, has not been fully addressed. Vepdegestrant is a f… |
Clinical Primary efficacy | ORR 57.98% |
Clinical ORR | 57.98% |
Clinical PFS | 19.3 |
Clinical OS | 49.1 |
Clinical Result source | ClinicalTrials.gov NCT05361655 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cyclin-Dependent Kinase 4 Inhibitor (Cyclin-Dependent Kinase 4 Inhibitor) SWOG Cancer Research Network·HER2 ORR 57.98% |
|---|---|
Overview Program | Cyclin-Dependent Kinase 4 Inhibitor |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | TArgeting Chimera (PROTAC) estrogen receptor |
MoA Biomarker | biomarker, Cyclin-dependent kinase 4 inhibitor A (p16INK4a) |
PK/PD Species | Mouse, ration assay, and a subcutaneous xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse, ration assay, and a subcutaneous xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Vepdegestrant for the treatment of HR+/HER2- breast cancer.. The treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer has been improved through the development of endocrine therapy (ET) and targeted agents. However, resistance to ET, particularly caused by ESR1 mutations, has not been fully addressed. Vepdegestrant is a f… |
Clinical Primary efficacy | ORR 57.98% |
Clinical ORR | 57.98% |
Clinical PFS | 19.3 |
Clinical OS | 49.1 |
Clinical Result source | ClinicalTrials.gov NCT05361655 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교